National Comprehensive Cancer Network



About NCCN

Acute Lymphoblastic Leukemia Panel - Disclosures as of 5/23/2013

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Joseph C. Alvarnas, MD

Clinical Trials Network

None

None

None

1/9/2013

Patricia Aoun, MD, MPH

None

None

None

None

3/26/2013

Karen Kuhn Ballen, MD

None

None

None

None

3/27/2013

Naresh Bellam, MD, MPH

None

None

None

None

2/9/2012

William Blum, MD

None

None

None

None

10/10/2012

Michael W. Boyer, MD

None

None

None

None

5/21/2012

Patrick A. Brown, MD

None

None

None

None

2/7/2013

Hetty E. Carraway, MD

None

None

None

None

3/26/2013

Peter F. Coccia, MD

None

None

None

None

12/21/2012

Steven E. Coutre, MD

None

Celgene Corporation

None

None

5/16/2013

Lloyd E. Damon, MD

Talon;
Sunesis Pharmaceuticals, Inc.

None

None

None

2/19/2013

Daniel J. DeAngelo, MD, PhD

None

Bristol-Myers Squibb Company;
Novartis Pharmaceuticals Corporation;
Sigma-Tau Pharmaceuticals, Inc.

None

None

3/16/2012

Dan Douer, MD

Enzon Pharmaceuticals

Enzon Pharmaceuticals

None

None

9/3/2012

Haydar Frangoul, MD

None

None

None

None

5/2/2012

Olga Frankfurt, MD

None

None

None

None

1/25/2012

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Robert A. Johnson, MD, FACP

None

None

None

None

3/25/2013

Joan S. McClure, MS

None

None

None

None

7/23/2012

Michael M. Millenson, MD, FACP

None

None

None

None

2/22/2013

Maoko Naganuma, MSc

None

None

None

None

2/28/2013

Susan O'Brien, MD

Hana Biosciences, Inc.

Hana Biosciences, Inc.

None

None

8/31/2012

Arati V. Rao, MD

None

None

None

None

3/9/2012

Bijal Shah, MD

Seattle Genetics;
Pfizer Inc.

None

None

None

8/30/2012

Andrei R. Shustov, MD

Talon Therapeutics;
Pfizer Inc.

None

None

None

8/30/2012

Geoffrey Uy, MD

Genzyme Corporation;
Novartis Pharmaceuticals Corporation

Genzyme Corporation

None

None

8/31/2012

Meir Wetzler, MD

Amgen Inc.;
Bristol-Myers Squibb Company

Amgen Inc.;
Teva

None

None

8/7/2012

Andrew D. Zelenetz, MD, PhD

Abbott Laboratories;
Celgene Corporation;
Cephalon, Inc.;
Genentech, Inc.;
GlaxoSmithKline;
Millennium Pharmaceuticals, Inc.;
Onyx Pharmaceuticals, Inc.;
Allos Pharm;
Calistoga;
Pharmacyclics;
Plexxikon;
Roche;
Seattle Genetics

Abbott Laboratories;
Celgene Corporation;
Cell Therapeutics, Inc.;
Cephalon, Inc.;
Genentech, Inc.;
GlaxoSmithKline;
Allos;
Cancer Genetics;
Gilead;
Seattle Genetics;
Roche Laboratories, Inc.;
sanofi-aventis U.S.

None

None

2/15/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved